Piramal Pharma Ltd

Desk›Healthcare› Piramal Pharma Ltd

BSE 543635 · NSE PPLPHARMA · ISIN INE0DK501011 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹218.60

+1.72%

BSE close, 28 August 2026

Market cap

₹29,103.27 cr

133.1 cr shares · Mid cap

Free float

₹13,542.13 cr

as published

P/E · P/B

41.6× · 4.15×

EPS ₹5.26 · BV ₹52.67

FY25-26 rev / PAT

4,782.01 / 700.01

₹ cr, as filed

Filings, window

8 selected · 27%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

Against 52-week high	-0.8%
Against 52-week low	+65.0%
Day change	+1.72%
Size band	Mid cap
Index membership	NIFTY 500

Valuation as published by BSE

Earnings per share	₹5.26
Price / earnings	41.56×
Price / book	4.15×
Book value — derived, price ÷ P/B	₹52.67
Return on equity	9.98%
Operating margin	20.58%
Net margin	10.09%

Consistency check

P/B ÷ P/E, which must equal ROE: 9.99%
ROE as published: 9.98%

Results ₹ crore, as filed

Jun-26 · Q

Mar-26 · Q

FY25-26

RevenueNet profit one scale across all three periods, ₹ crore

Period	Revenue ₹cr	Net profit ₹cr	EPS ₹	OPM	NPM
Jun-26 · Q	1,124.95	113.48	0.85	20.58%	10.09%
Mar-26 · Q	1,489.06	261.63	1.97	28.30%	17.57%
FY25-26	4,782.01	700.01	5.28	25.35%	14.64%

Quarter on quarter

Revenue, quarter on quarter: -24.5%
Net profit, quarter on quarter: -56.6%
Operating margin, quarter on quarter: -772 bps

Disclosure profile 30 filings in the window

Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.

Tag	Filings
Selected
Change in Management	2
Acquisition	1
Board Outcome	1
Concall Transcript	1
Investor Presentation	1
Press Release	1
Results	1
Selected sub-total	8
Procedural
General	11
Analyst / Investor Meet	4
AGM / EGM	2
SAST	2
Board Meeting	1
Clarification	1
Trading Window	1
Procedural sub-total	22
Total	30

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

30 filings · 8 selected · busiest 2026-07-29

Filing rhythm · the twelve most recent

2026-08-262026-10-01

SelectedProcedural

Filings

30 in the window · 11 earlier on record

1 October 2026 · 20:10 IST

General

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Expiry And Non-Renewal Of Commercial Arrangement With Bayer Pharmaceuticals Private Limited

Please refer attachment.

Company Update / General View filing →
1 October 2026 · 19:03 IST

General

543635 - Clarification On News Item Which Appeared In The 'Www.Thehindubusinessline.Com' Dated September 30, 2026 Captioned 'Ontario Contributes $1.7 Million Investment To Advance Life Sciences Innovation At Piramal Pharma'S Aurora Facility.'

Please refer attachment.

Company Update / General View filing →
30 September 2026 · 20:08 IST

Change in Management

Change in Management

Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 -Appointment of Senior Management Personnel.

Company Update / Change in Management View filing →
30 September 2026 · 17:55 IST

Change in Management

Change in Management

Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Changes in Senior Management Personnel.

Company Update / Change in Management View filing →
30 September 2026 · 17:53 IST

Clarification

Clarification sought from Piramal Pharma Ltd

The Exchange has sought Clarification from Piramal Pharma Ltd with reference to the media report appearing on https://www.thehindubusinessline.com/ dated September 30, 2026 (Link: https://www.thehindubusinessline.com/brandhub/pr-release/ontario-contributes-17-million-investment-to-advance-life-sciences-innovation-at-piramal-pharmas-aurora-facility/article71526588.ece) ....

Company Update / Clarification
29 September 2026 · 11:10 IST

Trading Window

Closure of Trading Window

Please refer the attachment.

Insider Trading / SAST / Closure of Trading Window View filing →
29 September 2026 · 10:59 IST

General

Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

Please refer attachment.

Company Update / General View filing →
18 September 2026 · 19:39 IST

General

543635 - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating -Niche Ninety Nine Capability And Certifications (OPC) Private Limited

Please refer attached file

Company Update / General View filing →
14 September 2026 · 19:50 IST

General

Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - FDA Inspection

Please refer attached file

Company Update / General View filing →
8 September 2026 · 15:33 IST

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Please refer attached file

Company Update / Analyst / Investor Meet View filing →
3 September 2026 · 14:28 IST

General

Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating

Please refer attached file

Company Update / General View filing →
26 August 2026 · 17:21 IST

SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG

Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
24 August 2026 · 17:01 IST

General

Sustainability Report Of Piramal Pharma Limited For The Financial Year 2025-26

Please refer attached file

Company Update / General View filing →
18 August 2026 · 11:34 IST

Acquisition

Acquisition

Please find enclosed intimation of acquisition of additional stake in Yapan Bio Private Limited

Company Update / Acquisition View filing →
18 August 2026 · 11:29 IST

SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG

Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
10 August 2026 · 18:02 IST

General

Exercise Of Call Option For Acquisition Of Additional Equity Stake In Yapan Bio Private Limited

Please find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited

Company Update / General View filing →
10 August 2026 · 14:18 IST

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Company Update / Analyst / Investor Meet View filing →
3 August 2026 · 17:29 IST

General

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -Resumption Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat

Please refer attachment

Company Update / General View filing →
31 July 2026 · 15:04 IST

Concall Transcript

Earnings Call Transcript

Please find enclosed details of Earning call Transcript held on 30th July 2026.

Company Update / Earnings Call Transcript View filing →
30 July 2026 · 20:15 IST

AGM / EGM

Shareholder Meeting / Postal Ballot-Scrutinizer's Report

Report of the Scrutinizer along with the voting results of the businesses transacted at the AGM

AGM/EGM / AGM View filing →
30 July 2026 · 20:12 IST

AGM / EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

Proceedings and Voting Results of the 6th Annual General Meeting of the Company

AGM/EGM / AGM View filing →
30 July 2026 · 12:17 IST

Analyst / Investor Meet

Analyst / Investor Meet - Outcome

Please find enclosed intimation of audio recordings of the conference call held today 30th July, 2026.

Company Update / Analyst / Investor Meet View filing →
29 July 2026 · 21:01 IST

Investor Presentation

Investor Presentation

Please see enclosed Investor Presentation for Q1 FY 27

Company Update / Investor Presentation View filing →
29 July 2026 · 20:58 IST

Press Release

Press Release / Media Release

Please see enlcosed Press Release for Q1 FY 27

Company Update / Press Release / Media Release View filing →
29 July 2026 · 20:51 IST

Results

Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June, 2026

Please find enlcosed UFR Q1 FY 27.

Result / Financial Results View filing →
29 July 2026 · 20:45 IST

Board Outcome

Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 29Th July, 2026

Please find enclosed outcome of Board Meeting of Piramal Pharma Limited held on 29th July, 2026

Board Meeting / Outcome of Board Meeting View filing →
29 July 2026 · 17:13 IST

General

Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Grant Of Stock Options

Grant of Stock Options pursuant to Piramal Pharma Limited - Employee Stock Option and Inc entive Plan 2022

Company Update / General View filing →
24 July 2026 · 20:42 IST

General

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Temporary Suspension Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat.

Please refer attachment.

Company Update / General View filing →
20 July 2026 · 12:53 IST

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Please find enclosed intimation of Analyst Meet scheduled to be held on 30th July 2026.

Company Update / Analyst / Investor Meet View filing →
20 July 2026 · 12:33 IST

Board Meeting

Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter Ended 30Th June, 2026.

Piramal Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....

Board Meeting / Board Meeting View filing →

RSS feed for Piramal Pharma Ltd · the 50 most recent filings

Price
Market cap
Sector
Index
PE
Latest quarter revenue
Net profit
Filings in the window